BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, released an update from Chairman Richard Staelin, PhD, detailing sales growth, strategic progress, and cost control measures. The company reported a small profit for calendar year 2025, attributed to relocating offices and reducing staff to align with operational needs.
Revenue-generating initiatives include targeted advertising campaigns aimed at medical professionals and healthcare providers to expand clinical awareness of RecoveryRx among surgeons, pain specialists, and chiropractors seeking non-opioid pain management options. The company has also expanded consumer-focused social media advertising targeting Generation X consumers to increase brand visibility for drug-free solutions for chronic musculoskeletal pain.
BioElectronics continues outreach to physician-owned ambulatory surgical centers and orthopedic practices to identify a clinical trial partner for RecoveryRx. The objective is to participate in a postoperative clinical study that may support future qualification for reimbursement under the federal NO PAIN Act initiative, which could drive broader adoption of non-opioid pain management technologies in surgical settings.
Internationally, the company is working with legal counsel in Singapore and funders in China regarding arbitration proceedings with a former distributor for alleged breach of contract. BioElectronics remains committed to protecting its intellectual property and contractual rights.
A key milestone is the strategic distribution and licensing relationship with Electrome Corporation. Initial conditions of the supply agreement have been satisfied, with Electrome placing its initial purchase order. Manufacturing is underway, and Electrome is planning a commercial launch of BioElectronics' pulsed shortwave therapy products. This partnership provides another pathway to increase consumer awareness and access to FDA-cleared, drug-free pain therapy products.
Chairman Staelin stated, 'Despite the challenges faced by emerging medical technology companies, we remain encouraged by the growing interest in non-drug pain management solutions and the long-term potential of our technology platforms.' He believes BioElectronics is well positioned in the evolving electroceutical and non-opioid pain management markets.
